Major bleeding episodes occur in people receiving anticoagulant therapy for venous thromboembolism
2004
Question
What is the clinical impact of bleeding in people taking anticoagulants for venous thromboembolism?
Study design
Systematic review with meta-analysis.
Main results
Thirty-three studies met inclusion criteria (29 randomised controlled trials, 4 prospective cohort studies; 10,757 people). Major bleeding occurred in (2.6%) of people receiving anticoagulant therapy for venous thromboembolism (see Table 1). Intracranial bleeding accounted for (8.7%) of all major bleeding episodes with fatalities occurring in (45.8%) of these episodes.
Table 1 Clinical impact of bleeding in people receiving anticoagulant therapy for venous thromboembolism.
Absolute risk (%) Absolute risk for fatal episodes (%) Rate of bleeding per 100 patient-years (95% CI)
Entire anticoagulation period
Major bleeding episodes 276/10,757 (2.6%) 37/276 (13.4%) 7.22 (7.19 to 7.24)
Intracranial bleeding episodes 24/8717 (0.3%) 11/24 (45.8%) 1.15 (1.14 to 1.16)
Full-size table
Table options
View in workspace
Download as CSV
Authors’ conclusions
Major bleeding associated with anticoagulant therapy has considerable clinical consequences that will need to be weighed against therapeutic benefits in people with venous thromboembolism.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
6
References
0
Citations
NaN
KQI